VXRT News and Press, Vaxart Inc. From 03/06/24

Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that it has appointed Steven Lo as President and C...

—  Data served as foundation for current vaccine candidate for planned Phase 2 research —  Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity against multiple variants of concern — ...

2024-02-01 05:14:33 ET Related stock stories: Rocket Lab: A Strong Buy On Growth Prospects And Backlog Strength Peloton Fiscal Q2 2024 Earnings Preview: Fitness Soap Opera Continues Rocket Lab: The Future Is Bright Deutsche Bank reports net profit of €...

2024-01-31 14:13:40 ET More on Vaxart Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript Vaxart gets BARDA funding for Phase 2 study of COVID-19 pill vaccine Vaxart announces $10M equity offering, key person steps down Seeking Alpha’s Quant Rating on...

2024-01-19 11:15:59 ET More on Vaxart Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript Vaxart announces $10M equity offering, key person steps down Vaxart Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Vaxart Historical earnings d...

- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - - Project NextGen is a $5 billion initiative by the U.S. Department of Health and Human Services to develop innovative vaccines and...

2024-01-16 10:21:55 ET More on Vaxart Vaxart Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Vaxart Historical earnings data for Vaxart Financial information for Vaxart For further details see: Vaxart to buyback $10M worth stock, k...

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering pri...

Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced a change in management. Effective immediately Andrei...

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...